Veru Inc
$ 2.61
5.24%
24 Feb - close price
- Market Cap 41,891,300 USD
- Current Price $ 2.61
- High / Low $ 2.70 / 2.45
- Stock P/E N/A
- Book Value 2.31
- EPS -1.21
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.43 %
- ROE -0.60 %
- 52 Week High 7.40
- 52 Week Low 2.10
About
Veru Inc., an oncology biopharmaceutical company, focuses on the development of drugs for the treatment of cancers. The company is headquartered in Miami, Florida.
Analyst Target Price
$25.00
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-11 | 2025-12-01 | 2025-08-12 | 2025-05-06 | 2025-02-06 | 2024-12-05 | 2024-08-08 | 2024-04-01 | 2024-02-14 | 2023-12-08 | 2023-08-10 | 2023-05-11 |
| Reported EPS | -0.26 | 0.09 | -0.5 | -0.0603 | -0.0713 | -0.052 | -0.07 | -0.08 | -0.08 | -0.12 | -0.13 | -0.48 |
| Estimated EPS | -0.47 | -0.0567 | -0.05 | -0.05 | -0.08 | -0.08 | -0.06 | -0.1 | -0.1 | -0.23 | -0.2 | -0.33 |
| Surprise | 0.21 | 0.1467 | -0.45 | -0.0103 | 0.0087 | 0.028 | -0.01 | 0.02 | 0.02 | 0.11 | 0.07 | -0.15 |
| Surprise Percentage | 44.6809% | 258.7302% | -900% | -20.6% | 10.875% | 35% | -16.6667% | 20% | 20% | 47.8261% | 35% | -45.4545% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Previous Dividend Records
| Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | None | None | None | None | None | None | None | None | None | None |
| Amount | $0.07 | $0.07 | $0.07 | $0.07 | $0.07 | $0.06 | $0.06 | $0.06 | $0.06 | $0.05 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: VERU
2026-02-19 13:27:41
Veru Inc. announced that its Chairman, President, and CEO, Mitchell Steiner, M.D., will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference. The presentation, scheduled for February 26, 2026, will highlight the company's focus on developing innovative medicines for cardiometabolic and inflammatory diseases, including its late-stage drug candidates enobosarm and sabizabulin. A webcast of the presentation will be available on the company's website.
2026-02-19 08:30:00
Veru Inc., a late clinical stage biopharmaceutical company, announced that its Chairman, President, and CEO, Mitchell Steiner, M.D., will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026. The presentation will cover the company's focus on developing medicines for cardiometabolic and inflammatory diseases, highlighting their late-stage assets enobosarm and sabizabulin. Enobosarm is being developed to enhance weight reduction and preserve lean mass in combination with GLP-1 RA drugs, with a planned Phase 2b PLATEAU clinical study to begin in Q1 2026.
2026-02-13 08:27:36
Veru Inc. reported a reduced net loss of $5.3 million in Q1 2026, an improvement from $8.9 million year-over-year. The company's stock rose by 6.06% in premarket trading following a successful public offering that raised $23.4 million, strengthening its financial position. Veru is advancing its strategic focus on innovative obesity treatments, particularly with enobosarm in combination with GLP-1 receptor agonists, and plans to initiate a Phase 2b PLATEAU clinical study this quarter.
2026-02-13 01:27:38
Veru (NASDAQ: VERU) announced a new Phase IIb clinical trial for its obesity drug, enobosarm, targeting an interim analysis in Q1 2027. The company's cash reserves increased to $104.9 million, bolstering its financial position. Veru's strategic focus is on advancing its drug pipeline and achieving key milestones in its clinical development.
2026-02-12 13:27:44
Veru Inc. reported its Q1 2026 earnings, beating expectations with an EPS of -$0.26254 against an expected -$0.47. The company discussed its advancements in developing Novosarm, a drug aimed at improving weight loss quality by preserving lean mass when combined with GLP-1 receptor agonists, and outlined its planned Phase 2b PLATO clinical study. Additionally, Veru Inc. provided financial highlights including a recent public offering that raised approximately $23.4 million and detailed shifts in R&D and G&A expenses.
2026-02-12 06:57:25
Veru (NASDAQ: VERU) has announced plans for a new Phase IIb trial for its obesity drug, enobosarm, which aims to provide a de-risked and accelerated path to Phase III. The company plans an interim analysis in Q1 2027 and has increased its cash reserves through a $100 million at-the-market offering and convertible debt refinancing. This strategic move aims to extend the cash runway through key data readouts for enobosarm and sabizabulin.
